Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dulpatatug + HLX87
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Dulpatatug + HLX87 is an investigational combination therapy being developed by Shanghai Henlius Biotech for the treatment of HER2-positive breast cancer. The regimen consists of dulpatatug (HLX22), a recombinant humanized monoclonal antibody that targets a novel epitope on subdomain IV of the HER2 extracellular region, and HLX87 (GQ1005), a next-generation HER2-directed antibody-drug conjugate (ADC) licensed from GeneQuantum Healthcare. Dulpatatug acts as a HER2 antagonist and binds to a distinct epitope from trastuzumab, allowing for synergistic HER2 receptor blockade, internalization, and degradation when combined with other HER2-targeted agents. HLX87 consists of an anti-HER2 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable, cleavable open-chain linker, designed to deliver strong bystander killing effects with minimized systemic toxicity. The combination is currently being evaluated in Phase 2/3 clinical trials as a first-line treatment for HER2-positive recurrent or metastatic breast cancer and as a neoadjuvant therapy for HER2-positive early or locally advanced breast cancer.
- Other names
- dulpatatug + GQ-1005dulpatatug + GQ1005dulpatatug + HLX87
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on dulpatatug + HLX87.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dulpatatug + HLX87.